Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy
7
Zitationen
7
Autoren
2010
Jahr
Abstract
In accordance with the recommended treatment objective for DA to minimise RBCTs, 81% of study patients remained free of RBCTs during DA 500 µg Q3W treatment and at an even higher rate if DA treatment was initiated before Hb fell below 9.0 g/dL.
Ähnliche Arbeiten
The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
1996 · 22.219 Zit.
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
2017 · 4.816 Zit.
Anemia of Chronic Disease
2005 · 3.718 Zit.
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 · 2.738 Zit.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 · 2.180 Zit.